Biothera Completes Second Phase I Clinical Trial for Cancer Drug
Posted on: Monday, 25 September 2006, 12:00 CDT
EAGAN, Minn., Sept. 25 /PRNewswire/ -- Biothera, the immune health company, announced today that it has successfully completed its second Phase I clinical trial for Imprime PGG(TM), its lead compound for activating the body's own immune system to fight multiple types of cancer.
The randomized, double-blind, placebo-controlled clinical study in healthy volunteers indicates that Imprime PGG is safe and well tolerated over a wide dose range. The results of the study support the continued development of the drug candidate in multiple indications.
The dose-escalation study evaluated safety, pharmacokinetic and pharmacodynamic responses at three dose levels (1, 2 and 4 mg/kg) administered intravenously daily for seven continuous days. This study followed a previous Phase I study in which Imprime PGG administered in single doses was also shown to be safe and well tolerated in healthy volunteers. A total of 36 volunteers participated in the two Phase I studies.
"The consistent results of these studies confirm our expectations and demonstrate that Imprime PGG has a strong safety profile," said Myra Patchen, Ph.D., Biothera executive vice president of pharmaceutical development. "We are looking forward to now quickly implementing our Phase II clinical program in cancer patients."
Biothera's Phase II clinical trial program is scheduled to begin in the fourth quarter of 2006.
"We are encouraged by these clinical findings and confident in the ability of Imprime PGG to work synergistically with monoclonal antibodies to treat numerous types of cancer," said Daniel Conners, Biothera founder and chairman.
Preclinical research demonstrated that the combination of Imprime PGG and various anti-cancer monoclonal antibodies significantly improved on the effectiveness of antibodies alone as evidenced by reductions in tumor size and increases in survival in multiple types of cancer, including breast, lung and liver cancer.
About Biothera, the Immune Health Company
Biothera is a biotechnology company dedicated to improving immune health. The company's primary focus is developing pharmaceuticals that engage the immune system to fight cancer. Pharmaceuticals are also in development to facilitate immune system recovery after damage from chemotherapy or acute radiation exposure. In addition, Biothera manufactures and markets food-grade ingredients that support healthy immune function to the nutritional supplement, functional food, cosmetic and animal nutrition markets. Website: http://www.biotherapharma.com/ .
Biothera
CONTACT: David Walsh, VP, Communications, of Biothera, the Immune HealthCompany, +1-651-256-4606, dwalsh@biotherapharma.com
Web site: http://www.biotherapharma.com/http://www.biopolymer.com/
Source: PRNewswire
Related Articles
- ProUroCare Medical Completes Multiple Site Clinical Study for Imaging Prostate Abnormalities
- Biothera to Present Imprime PGG(R) Clinical Trial Results at the International Society for Biological Therapy of Cancer
- Oncolytics Biotech Inc. Treats 200th Cancer Patient in Clinical Studies With REOLYSIN(R)
- Extended Accrual Time and Decreased Sample Size for OVATURE, a Multinational Phase III Clinical Study for Women With Recurrent Ovarian Cancer
- Biothera Initiates Phase Ib/IIa Clinical Trial With Imprime PGG and Erbitux in Metastatic Colorectal Cancer Patients
- Biothera's Imprime PGG Increases Efficacy of Erbitux Against Non-Small Cell Lung Cancer, Study Finds
- Epigenomics AG Demonstrates Feasibility of Convenient Blood Test for Lung Cancer Detection in Clinical Study
- Biothera's Imprime PGG(TM) Enhanced Effectiveness of Avastin(R) in Cancer Study
- Biothera Completes Phase I Clinical Trial for Imprime PGG
- Leading Cancer Centers Commence Clinical Study for Prostate Cancer Patients Receiving External Beam Radiation Therapy
 |
 |
User Comments (0)
RSS Feeds